Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

nasopharyngeal carcinoma, susceptibility to, 3 - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

nasopharyngeal carcinoma, susceptibility to, 3

MONDO:0014902

Also known as:MST1R nasopharyngeal carcinomaNPCA3nasopharyngeal carcinoma caused by mutation in MST1R

Overview

Any nasopharyngeal carcinoma in which the cause of the disease is a mutation in the MST1R gene.

GeneticsAutosomal dominant

OnsetADULT

Treatments1 FDA approved, newest 2025

Clinical Presentation

Features include common findings: Neoplasia of the nasopharynx.

Age of onset: adulthood.

Explore clinical features

Diagnosis

Biomarker and diagnostic research for nasopharyngeal carcinoma, susceptibility to, 3 has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for nasopharyngeal carcinoma, susceptibility to, 3, including PENPULIMAB (PENPULIMAB KCQX, approved 2025).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Phenotype severity distribution: 1 common feature.

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for nasopharyngeal carcinoma, susceptibility to, 3.

24 publications have been identified in PubMed for nasopharyngeal carcinoma, susceptibility to, 3. Research spans Basic Science / Preclinical (58%), Review / Meta-Analysis (13%), and Epidemiology / Natural History (13%).

Research Type	Count	% of Total
Laboratory research	14	58%

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 7:39 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:617075

Questions for Your Care Team

→What are the benefits and potential side effects of PENPULIMAB KCQX for managing nasopharyngeal carcinoma, susceptibility to, 3?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Kisho

nasopharyngeal carcinoma, susceptibility to, 3

Overview

Clinical Presentation

Explore clinical features

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

nasopharyngeal carcinoma, susceptibility to, 3

Overview

Clinical Presentation

Explore clinical features

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications